{"id":"https://openalex.org/W2913619009","doi":"https://doi.org/10.1182/blood-2018-99-114090","title":"Outcomes of Acute Myeloid Leukemia Patients with Indeterminate Day 14 Bone Marrow Results Treated with and without Re-Induction Chemotherapy","display_name":"Outcomes of Acute Myeloid Leukemia Patients with Indeterminate Day 14 Bone Marrow Results Treated with and without Re-Induction Chemotherapy","publication_year":2018,"publication_date":"2018-11-29","ids":{"openalex":"https://openalex.org/W2913619009","doi":"https://doi.org/10.1182/blood-2018-99-114090","mag":"2913619009"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2018-99-114090","doi":"https://doi.org/10.1182/blood-2018-99-114090","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-114090","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025907490","display_name":"OMER HASSAN JAMY","orcid":"https://orcid.org/0000-0003-2411-4742","observed_orcids":["https://orcid.org/0000-0003-2411-4742"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Omer Jamy","raw_affiliation_strings":["University of Alabama at Birmingham, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama at Birmingham, Birmingham, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075444717","display_name":"Charles Douglas Bodine","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles Bodine","raw_affiliation_strings":["UAB, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UAB, Birmingham, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019283877","display_name":"Sarmad Rehan","orcid":"https://orcid.org/0000-0003-3840-2710","observed_orcids":["https://orcid.org/0000-0003-3840-2710"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rehan Sarmad","raw_affiliation_strings":["University of Alabama at Birmingham, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama at Birmingham, Birmingham, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091428708","display_name":"Awalpreet Singh Chadha","orcid":"https://orcid.org/0000-0002-8072-2243","observed_orcids":["https://orcid.org/0000-0002-8072-2243"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Awal Chadha","raw_affiliation_strings":["UAB, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UAB, Birmingham, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038004259","display_name":"Pankit J. Vachhani","orcid":"https://orcid.org/0000-0001-9779-6217","observed_orcids":["https://orcid.org/0000-0001-9779-6217"]},"institutions":[{"id":"https://openalex.org/I1292894508","display_name":"Roswell Park Comprehensive Cancer Center","ror":"https://ror.org/0499dwk57","country_code":"US","type":"facility","lineage":["https://openalex.org/I1292894508"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pankit Vachhani","raw_affiliation_strings":["Roswell Park Cancer Institute, Buffalo, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Roswell Park Cancer Institute, Buffalo, NY","institution_ids":["https://openalex.org/I1292894508"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005850190","display_name":"Luciano J. Costa","orcid":"https://orcid.org/0000-0001-5362-2469","observed_orcids":["https://orcid.org/0000-0001-5362-2469"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Luciano J Costa","raw_affiliation_strings":["University of Alabama at Birmingham, Vestavia, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama at Birmingham, Vestavia, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086380393","display_name":"Ayman A Saad","orcid":"https://orcid.org/0000-0003-0003-0130","observed_orcids":["https://orcid.org/0000-0003-0003-0130"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ayman Saad","raw_affiliation_strings":["University of Alabama At Birmingham, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama At Birmingham, Birmingham, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032863911","display_name":"Nikolaos Papadantonakis","orcid":"https://orcid.org/0000-0003-1943-6421","observed_orcids":["https://orcid.org/0000-0003-1943-6421"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nikolaos Papadantonakis","raw_affiliation_strings":["University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050556099","display_name":"Harry Paul Erba","orcid":"https://orcid.org/0000-0003-1093-2189","observed_orcids":["https://orcid.org/0000-0003-1093-2189"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Harry P. Erba","raw_affiliation_strings":["University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103244395","display_name":"Antonio Di Stasi","orcid":"https://orcid.org/0000-0002-7886-3514","observed_orcids":["https://orcid.org/0000-0002-7886-3514"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Antonio Di Stasi","raw_affiliation_strings":["University of Alabama at Birmingham, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama at Birmingham, Birmingham, AL","institution_ids":["https://openalex.org/I32389192"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5103244395"],"corresponding_institution_ids":["https://openalex.org/I32389192"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"132","issue":"Supplement 1","first_page":"2688","last_page":"2688"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9990000128746033},{"id":"https://openalex.org/keywords/reinduction-chemotherapy","display_name":"reinduction chemotherapy","score":0.8690000176429749},{"id":"https://openalex.org/keywords/residual-disease","display_name":"residual disease","score":0.7950000166893005},{"id":"https://openalex.org/keywords/cytarabine","display_name":"cytarabine","score":0.6380000114440918},{"id":"https://openalex.org/keywords/anthracyclines","display_name":"anthracyclines","score":0.8529999852180481},{"id":"https://openalex.org/keywords/flt3-itd-mutation","display_name":"FLT3-ITD","score":0.847000002861023},{"id":"https://openalex.org/keywords/relapse","display_name":"relapse","score":0.3619999885559082},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.5600000023841858},{"id":"https://openalex.org/keywords/treatment-outcomes","display_name":"treatment outcomes","score":0.3930000066757202},{"id":"https://openalex.org/keywords/flow-cytometry","display_name":"flow cytometry","score":0.4300000071525574},{"id":"https://openalex.org/keywords/high-dose-cytarabine","display_name":"high-dose cytarabine","score":0.7329999804496765},{"id":"https://openalex.org/keywords/fludarabine","display_name":"fludarabine","score":0.8870000243186951},{"id":"https://openalex.org/keywords/granulocyte-colony-stimulating-factor","display_name":"granulocyte colony-stimulating factor","score":0.7269999980926514}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8579744100570679},{"id":"https://openalex.org/C2776611710","wikidata":"https://www.wikidata.org/wiki/Q16888295","display_name":"Induction chemotherapy","level":3,"score":0.8380368947982788},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.7363174557685852},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.6405515074729919},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.6285920143127441},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.5294627547264099},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5151389837265015},{"id":"https://openalex.org/C2779823535","wikidata":"https://www.wikidata.org/wiki/Q6865356","display_name":"Minimal residual disease","level":3,"score":0.4839211106300354},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4227708578109741},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.41817545890808105},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3607318103313446},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3320508599281311}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2018-99-114090","doi":"https://doi.org/10.1182/blood-2018-99-114090","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-114090","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2975036063","https://openalex.org/W4205120111","https://openalex.org/W2056070917","https://openalex.org/W2765458859","https://openalex.org/W4310108943","https://openalex.org/W2973013528","https://openalex.org/W2980890631","https://openalex.org/W2893462687","https://openalex.org/W2556677760","https://openalex.org/W2980599495"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"The":[2,31,200,287,335],"initial":[3],"response":[4,337,450],"to":[5,84,499],"standard":[6],"induction":[7,121],"chemotherapy":[8,35,97,122,291,480],"for":[9,98,129,176,393,455,485],"acute":[10],"myeloid":[11],"leukemia":[12],"(AML)":[13],"is":[14],"commonly":[15,289],"assessed":[16],"with":[17,24,38,65,72,88,93,123,144,230,245,262,344,462],"day":[18,40,67,100,146,169,464],"14":[19,41,68,101,147,170,465],"bone":[20,42,69,102,148,171,466],"marrow":[21,43,70,103,149,172,467],"evaluation;":[22],"patients":[23,37,64,87,115,143,155,178,211,228,309,461],"residual":[25],"disease":[26,417],"may":[27],"receive":[28],"re-induction":[29,34,75,96,158,182,214,237,254,277,295,313,321,375,378,469,479],"chemotherapy.":[30,76],"benefit":[32],"of":[33,62,428,477],"in":[36,46,117,210,220,235,251,271,275,280,293,311,318,351,363,389,434,448,459,488],"indeterminate":[39,66,99,145,463],"results":[44,104,150],"(defined":[45],"our":[47,60,112],"study":[48,131,440],"as":[49,197,248,250,452,454],"\u2264":[50],"20%":[51],"cellularity":[52],"and":[53,73,94,108,125,160,183,215,279,302,315,368,376,426,457,481,570,579,629,686],"5-20%":[54],"blasts)":[55],"remains":[56],"unclear.":[57],"We":[58,140],"report":[59],"experience":[61],"AML":[63,91,460],"treated":[71,92],"without":[74,95],"Methods:":[77],"A":[78],"retrospective":[79],"chart":[80],"review":[81],"was":[82,132,205,267,297,329,349,358,391],"performed":[83],"evaluate":[85],"adult":[86],"newly":[89],"diagnosed":[90],"between":[105,373],"January":[106],"2010":[107],"April":[109],"2018":[110],"at":[111,203,269,395,409],"institution.":[113],"All":[114,189],"included":[116],"the":[118,130,135,236,252,276,294,312,319,330,374,435,475,483],"analysis":[119],"received":[120,157,181,213,323],"cytarabine":[124,301,328],"an":[126],"anthracycline.":[127],"Approval":[128],"obtained":[133],"from":[134],"Institutional":[136],"Review":[137],"Board.":[138],"Results:":[139],"identified":[141],"50":[142],"(Table":[151],"1).":[152,381],"Twenty":[153],"five":[154],"(50%)":[156,162],"therapy":[159],"25":[161],"did":[163,187,223,441],"not.":[164,188,224,471],"Flow":[165],"cytometry":[166,191],"data":[167],"on":[168],"samples":[173],"were":[174,195,226],"available":[175],"15":[177],"(60%)":[179,310],"who":[180,186,212,222],"18":[184],"(72%)":[185],"flow":[190],"samples,":[192],"when":[193],"performed,":[194],"reported":[196],"persistent/residual":[198],"disease.":[199],"median":[201,364],"age":[202,394],"diagnosis":[204,270,396,410],"56":[206],"years":[207,217,399],"(range":[208,218],"19-70)":[209],"59":[216],"23-73)":[219],"those":[221],"There":[225,357],"12":[227],"(48%)":[229],"poor":[231],"risk":[232,418,421],"disease,":[233],"both":[234,352],"arm":[238,255,278,296,314,322],"(10":[239],"abnormal":[240,257],"karyotype,":[241,258],"2":[242,272],"normal":[243,260],"karyotype":[244,261],"molecular":[246,263],"abnormalities)":[247],"well":[249,453],"no":[253,320,359,377,385],"(6":[256],"6":[259],"abnormalities).":[264],"FLT3-ITD":[265],"mutation":[266],"positive":[268],"cases":[273,282],"(8%)":[274],"8":[281],"(32%)":[283],"not":[284,442],"receiving":[285,468],"re-induction.":[286],"most":[288],"used":[290],"regimen":[292,333],"fludarabine,":[298],"high":[299],"dose":[300],"granulocyte-colony":[303],"stimulating":[304],"factor":[305],"(FLAG,":[306],"56%).":[307],"Fifteen":[308],"17":[316],"(68%)":[317],"post-remission":[324],"consolidation":[325,332],"therapy.":[326],"High-dose":[327],"preferred":[331],"(96%).":[334],"overall":[336,365,449],"rate":[338],"[complete":[339],"remission":[340],"(CR)":[341],"+":[342],"CR":[343],"incomplete":[345],"count":[346,408],"recovery":[347],"(CRi)]":[348],"similar":[350,495],"arms":[353,379],"(80%":[354],"vs.":[355,400,413,422,431],"80%).":[356],"statistically":[360,386,445],"significant":[361,387,446],"difference":[362,388,447],"survival":[366,371],"(OS)":[367],"relapse":[369],"free":[370],"(RFS)":[372],"(Figure":[380],"In":[382],"univariate":[383],"analysis,":[384],"OS":[390,456],"found":[392],"(\u2265":[397,411],"60":[398,402],"<":[401,414],"years;":[403],"p=0.06),":[404],"white":[405],"blood":[406],"cell":[407],"50,000":[412],"50,000;":[415],"p=0.48),":[416],"status":[419],"(poor":[420],"favorable/intermediate":[423],"risk;":[424],"p=0.81)":[425],"performance":[427],"transplant":[429],"(yes":[430],"no;":[432],"p=0.13)":[433],"entire":[436],"population.":[437,491],"Conclusion:":[438],"Our":[439,472],"find":[443],"a":[444],"rates,":[451],"RFS":[458],"or":[470],"findings":[473],"question":[474],"utility":[476],"immediate":[478],"raise":[482],"concern":[484],"over":[486],"treatment":[487],"this":[489],"patient":[490],"Larger":[492],"studies":[493],"investigating":[494],"outcomes":[496],"are":[497],"warranted":[498],"validate":[500],"these":[501],"clinical":[502],"findings.":[503],"Table":[504,506],"1.":[505,507],"Disclosures":[508],"Costa:":[509],"Celgene:":[510,606,633,667,757],"Honoraria,":[511,518,536],"Research":[512,515,519,522,525,530,541,546,553,560,563,586,595,598,601,604,615,618,622,640,645,652,662,665,676,679,691,694,697,704,713,718,721,724,728,741,779,782],"Funding;":[513,516,520,523,526,542,547,554,561,564,587,596,599,602,605,616,619,623,641,646,653,663,666,677,680,692,695,698,705,714,719,722,725,729,742,780,783],"Abbvie:":[514],"Amgen:":[517,562,617,693,696],"Janssen:":[521,603,703,723],"Karyopharm:":[524],"Sanofi:":[527],"Honoraria;":[528],"BMS:":[529],"Funding.":[531],"Saad:Actinium:":[532],"Consultancy.":[533],"Papadantonakis:Agios":[534],"pharmaceuticals:":[535],"Other:":[537,567,576,626,649,683,734,755,767],"advisory":[538],"board.":[539],"Erba:Janssen:":[540],"Daiichi":[543,550,583,637],"Sankyo:":[544,551,584,638],"Consultancy,":[545,552,556,566,575,585,589,594,607,611,621,625,634,639,644,648,655,661,668,672,682,700,707,712,717,727,733,737,746,750,754,758,762,766,770,774,778,785,789,793],"MacroGenics:":[548,658,730,743],"Consultancy;":[549,659,731,744],"Incyte:":[555,745,784,788],"Speakers":[557,590,608,612,635,656,669,673,701,708,738,747,751,759,763,771,775,786,790,794],"Bureau;":[558,591,609,613,636,657,670,674,702,709,739,748,752,760,764,772,776,787,791],"Juno:":[559,614,664,740],"Glycomimetics:":[565,574,624,681],"Chair,":[568,577,627,684],"Data":[569,578,628,685],"Safety":[571,580,630,687],"Monitoring":[572,581,631,688],"Committee;":[573,582,632,689],"Agios:":[588,654,736,761],"Seattle":[592,642,710,715],"Genetics:":[593,643,711,716],"Astellas:":[597,651,678,781],"Takeda/Millenium:":[600,675,690,720],"Novartis:":[610,671,699,749],"Immunogen:":[620,660,726,777],"Pfizer:":[647,732,753,765],"grant;":[650,735,756,768],"Jazz:":[706,769,773,792],"Bureau.":[795]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2019-02-21T00:00:00"}